Low Carbohydrate Portfolio or "Eco-Atkins" Diet
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00256516|
Recruitment Status : Completed
First Posted : November 21, 2005
Last Update Posted : May 20, 2013
|Condition or disease||Intervention/treatment||Phase|
|Hypercholesterolemia Cardiovascular Diseases||Other: Eco-Atkins diet (high vegetable protein and vegetable fat) Other: NCEP diet||Phase 2|
Subjects: Thirty overweight hyperlipidemic subjects who wish to lose weight.
- Protocol (Metabolic Study): will be randomized to either the Eco-Atkins diet (15 subjects) or NCEP diet (15 subjects). The diets will be provided for the one month period with the aim of inducing the same weight loss (5 kg) as seen in the first month of the published reports on the Atkins diet. The diets will provide about 60% of estimated energy requirements. Subjects will be provided with their diets at weekly intervals by courier and intakes adapted to ensure that they achieve their target weight loss goal. Fasting weight will be taken at weekly intervals together with blood pressure and blood for lipids, glucose and insulin assessment.
- Protocol (Ad Libitum Study): After completing the metabolic phase of the study, the thirty subjects will be asked to continue with the diet to which they were randomized for a further 6-month period. During this ad libitum trial, study foods will not be provided. This longer less tightly controlled study will establish the value of this diet in "real life" situations. This will be required to support our shorter term, well-controlled more detailed metabolic study. Fasting weight will be taken at monthly intervals together with blood pressure and blood for lipids, glucose and insulin assessment.
Study Details: Participants will come after a 12h overnight fast to the Risk Factor Modification Centre at St. Michael's Hospital or the Department of Nutritional Sciences, University of Toronto immediately prior to commencement of each treatment phase and at weekly intervals during the metabolic study and monthly during the ad libitum study. Prior to the start of the study, participants will be instructed on details of the study diet protocol. They will also be asked to maintain a constant level of physical activity throughout the course of the study. At all visits, body weight (in kg) will be obtained in indoor clothing, without shoes, and blood pressure will be taken twice in the dominant arm after participants have been seated for at least 20 minutes. Height (in cm) will be recorded at the first visit. Body composition measurements will be measured using bioelectric impedance at baseline and week 4 of the metabolic phase, and months 3 and 6 of the ad libitum phase. Throughout the study period, participants will maintain the diet prescribed on their initial visit. At each visit, participants will provide a fasting blood sample and seven-day food records will be collected. During the last week of the metabolic and ad libitum study, 24h fecal and urine collections will be completed.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Low Carbohydrate Portfolio or "Eco-Atkins" Diet|
|Study Start Date :||April 2005|
|Study Completion Date :||December 2006|
|Experimental: Eco-Atkins diet||Other: Eco-Atkins diet (high vegetable protein and vegetable fat)|
|Active Comparator: NCEP diet||Other: NCEP diet|
- total and low-density lipoprotein (LDL) cholesterol
- LDL:HDL cholesterol ratio
- weight reduction
- blood pressure
- high-density lipoprotein (HDL) cholesterol
- HDL2 and HDL3, triglyceride, apolipoprotein A1 and B, Lp(a) and LDL particle size
- glucose, insulin and measurements of oxidative stress
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00256516
|Risk Factor Modification Centre, St. Michael's Hospital|
|Toronto, Ontario, Canada, M5C 2T2|
|Principal Investigator:||David JA Jenkins, MD, PhD, DSc||University of Toronto and St. Michael's Hospital|